Generic Weight Loss Drugs May Soon Lower Costs in Canada
Jan. 7, 2026
Health Canada Reviews New Submissions
Canadians may soon see lower prices for popular weight loss medications. Health Canada has confirmed it is reviewing nine submissions for generic versions of widely used obesity drugs, a move that experts say could significantly reduce costs.
These applications involve generic forms of semaglutide, the active ingredient in Ozempic and Wegovy, two injectable prescription medications developed by Novo Nordisk. Health Canada has already approved Ozempic for diabetes treatment and Wegovy for weight loss.
Potential Impact on Drug Prices
Experts believe that introducing generic versions could increase competition in the market. As a result, patients may gain access to more affordable treatment options for obesity and related health conditions.
Currently, brand-name semaglutide medications remain expensive and out of reach for many Canadians. Therefore, the approval of generics could ease financial pressure on both patients and the healthcare system.
Questions About Pill-Based Versions
In addition to injectable drugs, CBC News asked Health Canada whether it has received an application for a pill form of Wegovy, either from Novo Nordisk or from a generic manufacturer.
In response, the regulator explained that it does not publicly confirm the timing of submissions filed by drug manufacturers. However, Health Canada regularly updates its Submissions Under Review list, which outlines applications accepted for evaluation.
Regulatory Review Continues
Health Canada stated on Wednesday that it continues to assess submissions based on safety, quality, and effectiveness. While the review process takes time, the growing number of applications suggests progress toward broader access to obesity treatments.
If approved, these generic medications could mark an important step toward improving affordability and availability for Canadians seeking medical support for weight management.
NEWS DESK
PRESS UPDATE